NCT06682936 Feasibility of Ambulatory Talc. Pleurodesis
| NCT ID | NCT06682936 |
| Status | Recruiting |
| Phase | — |
| Sponsor | David Rollins |
| Condition | Malignant Pleural Effusion |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2024-01-10 |
| Primary Completion | 2025-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 15 participants in total. It began in 2024-01-10 with a primary completion date of 2025-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients with malignant pleural disease often experience a significant symptom burden and a short life expectancy. The cornerstone of their treatment is relieving breathlessness by draining fluid from around the lungs and attempting to prevent further fluid build up. Inpatient chest drainage and talc pleurodesis remains the most successful method of stopping the fluid build up but this often requires an average hospital stay of four days. This can be an inappropriate length of time for this patient group. Our study would investigate whether this treatment could be provided on an outpatient, ambulatory basis and facilitate a greater quality of life. The investigators would assess deliverability of the trial protocol and collect patient feedback to see if our patients consider it an acceptable and worthwhile intervention.
Eligibility Criteria
Inclusion Criteria: * Malignant pleural effusion * Life expectancy \>30 days * WHO PS 1-2 (3 if due to dyspnoea) Exclusion Criteria: * Previous failed pleurodesis (on affected side) * Known non-expansile lung
Contact & Investigator
Kevin Conroy, MBBS, FRCP
PRINCIPAL INVESTIGATOR
University Hospital of North Tees
Frequently Asked Questions
Who can join the NCT06682936 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Malignant Pleural Effusion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06682936 currently recruiting?
Yes, NCT06682936 is actively recruiting participants. Contact the research team at kevin.conroy@nhs.net for enrollment information.
Where is the NCT06682936 trial being conducted?
This trial is being conducted at Stockton-on-Tees, United Kingdom.
Who is sponsoring the NCT06682936 clinical trial?
NCT06682936 is sponsored by David Rollins. The principal investigator is Kevin Conroy, MBBS, FRCP at University Hospital of North Tees. The trial plans to enroll 15 participants.